Combination treatment for diabetes mellitus
The invention relates to combinations of (2R,4aR,10bR)-6-(2,6-Dimethoxy-pyridin-3-yl)-9-ethoxy-8-methoxy-1,2,3,4,4a,10b-hexahydrophenanthridine-2-ol with other active compounds for the treatment of diabetes mellitus type 2 and/or type 1.
1 . A pharmaceutical composition comprising a pharmaceutical formulation including (2R,4aR,10bR)-6-(2,6-Dimethoxy-pyridin-3-yl)-9-ethoxy-8-methoxy-1,2,3,4,4a,10b-hexahydrophenanthridine-2-ol or a pharmaceutically acceptable salt thereof, one other active compound or a pharmaceutically acceptable salt thereof which is used in the treatment of diabetes mellitus type 2 and/or type 1, and at least one pharmaceutically acceptable auxiliary.
2 .- 13 . (canceled)
14 . Pharmaceutical composition according to claim 1 wherein the other active compound which is used in the treatment of diabetes mellitus type 2 and/or type 1 is a sulfonylurea agent or a pharmaceutically acceptable salt thereof.
15 . Pharmaceutical composition according to claim 14 wherein the sulfonylurea agent is selected from the group consisting of TOLBUTAMIDE, TOLAZAMIDE, GLIPIZIDE, CARBUTAMIDE, GLISOXEPIDE, GLISENTIDE, GLIBORNURIDE, GLIBENCLAMIDE, GLIQUIDONE GLIMEPIRIDE, GLICLAZIDE and the pharmaceutically acceptable salts of these compounds.
16 . Pharmaceutical composition, combination according to claim 1 wherein the other active compound which is used in the treatment of diabetes mellitus type 2 and/or type 1 is a biguanide agent or a pharmaceutically acceptable salt thereof.
17 . Pharmaceutical composition according to claim 16 wherein the biguanide agent is METFORMIN or a pharmaceutically acceptable salt of this compound.
18 .- 19 . (canceled)
20 . Pharmaceutical composition according to claim 1 wherein the other active compound which is used in the treatment of diabetes mellitus type 2 and/or type 1 is a PPAR-agonist or a pharmaceutically acceptable salt thereof.
21 . Pharmaceutical composition according to claim 20 wherein the PPAR-agonist is selected from the group consisting of MURAGLITAZAR, ROSIGLITAZONE, PIOGLITAZONE, FARGLITAZAR, NAVEGLITAZAR, NETOGLITAZONE, RIVOGLITAZONE, K-111, GW-677954, (−)-Halofenate and the pharmaceutically acceptable salts of these compounds.
22 .- 60 . (canceled)
61 . A method for treating diabetes mellitus type 2 and/or type 1 comprising administering to a patient in need thereof a pharmaceutical composition comprising a pharmaceutical formulation including an amount of (2R,4aR,10bR)-6-(2,6-Dimethoxy-pyridin-3-yl)-9-ethoxy-8-methoxy-1,2,3,4,4a,10b-hexahydrophenanthridine-2-ol or a pharmaceutically acceptable salt thereof, an amount of one other active compound or a pharmaceutically acceptable salt thereof which is used in the treatment of diabetes mellitus type 2 and/or type 1, wherein the first amount and the second amount together comprise an effective amount for the treatment of diabetes mellitus type 2 and/or type 1, and at least one pharmaceutically acceptable auxiliary.
62 .- 71 . (canceled)
72 . The method according to claim 61 wherein the other active compound which is used in the treatment of diabetes mellitus type 2 and/or type 1 is a sulfonylurea agent or a pharmaceutically acceptable salt thereof.
73 . The method according to claim 72 wherein the sulfonylurea agent is selected from the group consisting of TOLBUTAMIDE, TOLAZAMIDE, GLIPIZIDE, CARBUTAMIDE, GLISOXEPIDE, GLISENTIDE, GLIBORNURIDE, GLIBENCLAMIDE, GLIQUIDONE, GLIMEPIRIDE, GLICLAZIDE and the pharmaceutically acceptable salts of these compounds.
74 . The method according to claim 61 wherein the other active compound which is used in the treatment of diabetes mellitus type 2 and/or type 1 is a biguanide agent or a pharmaceutically acceptable salt thereof.
75 . The method according to claim 74 wherein the biguanide agent is METFORMIN or a pharmaceutically acceptable salt of this compound.
76 .- 77 . (canceled)
78 . The method according to claim 61 wherein the other active compound which is used in the treatment of diabetes mellitus type 2 and/or type 1 is a PPAR-agonist or a pharmaceutically acceptable salt thereof.
79 . The method according to claim 78 wherein the PPAR-agonist is selected from the group consisting of MURAGLITAZAR, ROSIGLITAZONE, PIOGLITAZONE, FARGLITAZAR, NAVEGLITAZAR, REGLITAZAR, NETOGLITAZONE, RIVOGLITAZONE, K-111, GW-677954, (−)-Halofenate and the pharmaceutically acceptable salts of these compounds.
80 .- 115 . (canceled)